Lifted this time line out of their blue book listing . Looks...

Lifted this time line out of their blue book listing . Looks like things are finally on track to meet the dates on the big two [cancer/psoriasis] , with the end points of the phase 1 in cancer already met and the psoriasis trial already in the final stage .
Main Company R&D Projects - Major Technology & Market
1: SBP002 Cancer
Target Market: Cancer $5B pa Coramsine™ (Solasodine Glycosides) has been shown to exhibit strong anticancer activity in specific cancer cell lines in animals and humans despite being relatively non-toxic to normal cells. The combination of anti-cancer effectiveness and avoidance of many undesirable side-effects associated with most chemotherapy agents is highly desirable. Coramsine™’s mode of action is unique. It is in Phase I/IIA studies assessing safety and preliminary efficacy in late stage cancer patients with solid tumours unresponsive to current treatments.
Stage: Phase I/IIA
Target Date: Finish 1Q 2005

2: SBP002 Psoriasis
Target Market: Psoriasis $3B pa Coramsine™ also modulates production of the cytokine Interleuken-6 (IL-6), which has been implicated in inflammatory diseases (eg rheumatoid arthritis, psoriasis) and other diseases such as Alzheimer’s disease and arteriosclerosis. Solbec has lodged patents to cover IL-6 activity and Phase I/II Coramsine™ studies in healthy people and chronic psoriasis patients are about to commence.
Stage: Phase I/IIA
Target Date: Finish 1Q 2005

3: Cancer Diagnostics
Target Market: Cancer Diagnostics Solbec’s Coramsine™ patents cover a range of diagnostic applications and specific diagnostic test opportunities have been identified. Preliminary studies designed to confirm the diagnostic potential of Coramsine™ have shown promising results to date. We are looking for a strategic partner to co-develop diagnostic products.
Stage: Development
Target Date: Mid 2005

4: Skin Cancer in Animals
Target Market: Veterinary Coramsine™ has been shown to be active against a number of skin cancers in animals. Preliminary proof of principle studies have shown good activity against squamous cell and basal cell carcinoma as well as melanoma in cats, dogs and horses. Solbec are currently talking to potential partners and hope to be in a position to co-develop a project in this area over the next 6 to 9 months.
Stage: Pre-Clinical Studies
Target Date: 2nd Q 2005